0001209191-22-019723.txt : 20220317 0001209191-22-019723.hdr.sgml : 20220317 20220317175402 ACCESSION NUMBER: 0001209191-22-019723 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220315 FILED AS OF DATE: 20220317 DATE AS OF CHANGE: 20220317 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Foley Mark J CENTRAL INDEX KEY: 0001529196 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-36297 FILM NUMBER: 22750137 MAIL ADDRESS: STREET 1: ZELTIQ AESTHETICS INC. STREET 2: 4698 WILLOW ROAD SUITE 100 CITY: PLEASANTON STATE: CA ZIP: 94588 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Revance Therapeutics, Inc. CENTRAL INDEX KEY: 0001479290 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770551645 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1222 DEMONBREUN STREET STREET 2: SUITE 2000 CITY: NASHVILLE STATE: TN ZIP: 37203 BUSINESS PHONE: 6157247755 MAIL ADDRESS: STREET 1: 1222 DEMONBREUN STREET STREET 2: SUITE 2000 CITY: NASHVILLE STATE: TN ZIP: 37203 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2022-03-15 0 0001479290 Revance Therapeutics, Inc. RVNC 0001529196 Foley Mark J C/O REVANCE THERAPEUTICS, INC. 1222 DEMONBREUN STREET, SUITE 2000 NASHVILLE TN 37203 1 1 0 0 Chief Executive Officer Common Stock 2022-03-15 4 F 0 3304 15.79 D 765761 D Common Stock 110913 I See footnote Represents the number of shares withheld by and surrendered to the Issuer on March 15, 2022, to satisfy tax withholding obligations that arose in connection with the vesting of Restricted Stock award (the "RSA") for 40,715 shares. The RSA vests in three equal annual installments from March 15, 2021, subject to Mr. Foley's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan) on each vesting date. These shares are held by the Mark and Dana Foley, Trustees, Foley Family Trust U/A DTD 4/10/2002. /s/ Terri McDowell, Attorney-in-Fact 2022-03-17